| Tiffany Bruckner, CNP | |
|
201 S Lloyd St Ste E201, Aberdeen, SD 57401-4509 | |
| (605) 622-2545 | |
| (605) 229-5331 |
| Full Name | Tiffany Bruckner |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 201 S Lloyd St Ste E201, Aberdeen, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801201439 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | CP000859 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera St Lukes | Aberdeen, SD | Hospital |
| Marshall County Healthcare Center - Cah | Britton, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Avera St Lukes | 6406764927 | 132 |
News Archive
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
A third of Americans are now obese, and up to 70% of them are trying to lose weight. In a new study published in the American Journal of Preventive Medicine, researchers from Harvard Medical School and Beth Israel Deaconess Medical Center in Boston have found in a nationally representative sample that obese dieters who said they ate less fat, exercised more, and used prescription weight loss medications were more likely to lose weight.
A common type of treatment used to protect bone density in menopausal women is also an effective therapy for advanced prostate cancer patients during the first year of hormone therapy, according to a new Oregon Health & Science University Cancer Institute study.
Given that cancer is ultimately a genetic disease, it has long been the hope of researchers to use gene therapy to attack tumors where they might be most susceptible.
› Verified 1 days ago
| Entity Name | Avera St Lukes |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215100813 PECOS PAC ID: 6406764927 Enrollment ID: O20040120000912 |
News Archive
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
A third of Americans are now obese, and up to 70% of them are trying to lose weight. In a new study published in the American Journal of Preventive Medicine, researchers from Harvard Medical School and Beth Israel Deaconess Medical Center in Boston have found in a nationally representative sample that obese dieters who said they ate less fat, exercised more, and used prescription weight loss medications were more likely to lose weight.
A common type of treatment used to protect bone density in menopausal women is also an effective therapy for advanced prostate cancer patients during the first year of hormone therapy, according to a new Oregon Health & Science University Cancer Institute study.
Given that cancer is ultimately a genetic disease, it has long been the hope of researchers to use gene therapy to attack tumors where they might be most susceptible.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tiffany Bruckner, CNP Po Box 1460, Aberdeen, SD 57402-1460 Ph: (605) 622-2857 | Tiffany Bruckner, CNP 201 S Lloyd St Ste E201, Aberdeen, SD 57401-4509 Ph: (605) 622-2545 |
News Archive
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
A third of Americans are now obese, and up to 70% of them are trying to lose weight. In a new study published in the American Journal of Preventive Medicine, researchers from Harvard Medical School and Beth Israel Deaconess Medical Center in Boston have found in a nationally representative sample that obese dieters who said they ate less fat, exercised more, and used prescription weight loss medications were more likely to lose weight.
A common type of treatment used to protect bone density in menopausal women is also an effective therapy for advanced prostate cancer patients during the first year of hormone therapy, according to a new Oregon Health & Science University Cancer Institute study.
Given that cancer is ultimately a genetic disease, it has long been the hope of researchers to use gene therapy to attack tumors where they might be most susceptible.
› Verified 1 days ago
Ashley Marie Landis, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 701 8th Ave Nw, Suite A, Aberdeen, SD 57401 Phone: 605-226-2663 | |
Lindsay Habeck, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3015 3rd Ave Se, Aberdeen, SD 57401 Phone: 605-226-5500 | |
Matthew R Lutjens, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 105 S State St Ste 113, Aberdeen, SD 57401 Phone: 605-225-0378 Fax: 605-225-7919 | |
Ms. Valerie Anne Jones, CNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1315 6th Ave Se, Suite 6, Aberdeen, SD 57401 Phone: 605-225-1538 Fax: 605-229-2053 | |
Kristine Lynn Fastenau, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 310 S Penn St Ste 203, Aberdeen, SD 57401 Phone: 605-225-7326 | |
Alisa Hogue, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 310 S Penn St, Suite 202, Aberdeen, SD 57401 Phone: 605-622-2895 Fax: 605-622-2896 | |
Sara Hegg, CNP, WHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2120 8th Ave Ne, Aberdeen, SD 57401 Phone: 605-725-4772 Fax: 605-725-4777 |